Frontlight ResearchEarly access
TerminatedPhase 1/2
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
Key facts
- Who runs it
- Incyte Corporation
- Where
- Cincinnati, Detroit, Houston, Miami, Nashville, New Orleans, Palo Alto, and Sarasota, United StatesSee the 8 sitesAlso in 2 other countries, 7 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 22 people enrolled
- Started
- 19 Aug 2021
- Ended
- 15 Aug 2024
- Type of study
- Interventional
- Treatments tested
- INCB000928
- Record updated
- 22 October 2025
- Why it stopped
- Strategic Business Decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Agreement to avoid pregnancy or fathering children
- Participants who are transfusion-dependent or present with symptomatic anemia; For MDS participants:
- Ineligible to receive or have not responded to available therapies for anemia such as ESAs or lenalidomide
- Not requiring cytoreductive therapy other than hydroxyurea
- BM and peripheral blood myeloblast count < 10%
- Histologically confirmed diagnosis of the MDS, CMML and unclassifiable MDS/MPN overlap syndromes; For MM participants:
- Histologically confirmed diagnosis of MM
- After failure of available standard treatments such as alkylating agents, glucocorticoids, immunomodulatory drugs (lenalidomide,pomalidomide, or thalidomide), proteasome inhibitors (bortezomib or carfilzomib), and daratumumab
Who cannot take part
- Any prior allogeneic stem cell transplantation or a candidate for such transplantation
- Any major surgery within 28 days before the first dose of study drug
- Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, or antibody or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug
- Undergoing treatment with another investigational medication or having been treated with an investigational medication within 28 days before the first dose of study drug. -Undergoing treatment with ESAs, granulocyte colony-stimulating factor or granulocyte/macrophage colony-stimulating factor, romiplostin, or eltrombopag at any time within 28 days before the first dose of study drug
- Undergoing treatment with a strong or potent inhibitor or inducer of CYP3A4/5 within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug or expected to receive such treatment during the study
- History of clinically significant or uncontrolled cardiac disease
- Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
- Diagnosis of chronic liver disease
- History or presence of an abnormal ECG that, in the investigator's opinion, is clinically Meaningful
Where in United States
Also in 2 other countries, 7 sites
- University of CincinnatiCincinnati, United States
- Barbara Ann Karmanos Cancer HospitalDetroit, United States
- MD Anderson Cancer CenterHouston, United States
- University of MiamiMiami, United States
- Vanderbilt University Medical CenterNashville, United States
- Tulane Comprehensive Cancer CenterNew Orleans, United States
- Stanford Cancer CenterPalo Alto, United States
- Florida Cancer SpecialistsSarasota, United States
About the trial
What the trial wants to find out
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
The group in the trial
- INCB000928Treatment being tested
INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
- Record updated
- 22 October 2025